Close
Achema middle east
swop processing & packaging

Russia’s Sputnik V likely to be available for supply from January

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sofinnova Partners Raises $750mn to Support Biotech Startups

European venture capital firm Sofinnova Partners said on November...

J&J Buys Halda for $3bn to Own the Cell Death Platform

Johnson & Johnson will be paying $3.05 billion so...

Pharma Grade Supplements vs. Food Grade Supplements

In recent years, dietary supplements have become a major...

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Governor Jenniffer A. González Colón, along with Sebastián Negrón...
- Advertisement -

Russia’s Sputnik-V COVID-19 vaccine might become available for supply as early as next month, the country’s sovereign wealth fund RDIF’s top official told ThePrint.

According to Kirill Dmitriev, the Chief Operating Officer (COO) of RDIF, they are hoping for approval in January 2021, and are “ready to supply the vaccine to a wider population within the same timeframe”.

“As we understand, the country’s government is working on a special Covid-19 inoculation programme that would be using the processes, technology and network of the Universal Immunisation Programme (UIP) currently in place,” Dmitriev said while talking about the distribution process of the vaccine once it receives approval.

“Strengthening the cold chain systems and deploying trained personnel to ensure vaccine safety would be key to the inoculation process’s ultimate success. Another important thing would be to prioritise socio-demographic groups that would be among the first to gain access to the vaccine apart from healthcare professionals,” he added.

 

Latest stories

Related stories

Sofinnova Partners Raises $750mn to Support Biotech Startups

European venture capital firm Sofinnova Partners said on November...

J&J Buys Halda for $3bn to Own the Cell Death Platform

Johnson & Johnson will be paying $3.05 billion so...

Pharma Grade Supplements vs. Food Grade Supplements

In recent years, dietary supplements have become a major...

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Governor Jenniffer A. González Colón, along with Sebastián Negrón...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »